Median Technologies has appointed Oran Muduroglu as president of its U.S. subsidiary, Median eyonis, to lead the commercial launch of eyonis LCS.
The eyonis LCS is Median's AI-based lung cancer screening software, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Muduroglu has more than three decades of experience in medical imaging, including co-founding Stentor, acquired by Philips in 2005, and serving as CEO of Medicalis, acquired by Siemens Healthineers in 2017. He will continue to serve as executive chairman of Median's board of directors while leading U.S. operations.
Median said it has activated a phased U.S. launch strategy and expects its first U.S. sites to be operational in the third quarter of 2026. The company announced a nonexclusive distribution agreement with Tempus AI on February 12, integrating eyonis LCS into Tempus' Pixel platform, and said it plans additional distribution agreements with imaging, cloud, and diagnostics partners.
Eyonis LCS is reimbursable under the Centers for Medicare and Medicaid Services' New Tech Ambulatory Payment Classifications pathway, with Medicare paying approximately $601 to $700 per exam in 2026, according to Median.
